CINECA IRIS Institutional Research Information System

BOGLIONE, Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.219
EU - Europa 2.990
AS - Asia 1.166
AF - Africa 48
OC - Oceania 14
SA - Sud America 14
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.456
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.173
CN - Cina 608
DK - Danimarca 580
IT - Italia 498
IE - Irlanda 374
SE - Svezia 342
DE - Germania 241
SG - Singapore 240
FR - Francia 217
UA - Ucraina 167
AT - Austria 148
FI - Finlandia 130
GB - Regno Unito 112
VN - Vietnam 63
IN - India 62
KR - Corea 55
NL - Olanda 44
CA - Canada 35
ID - Indonesia 32
PL - Polonia 27
HK - Hong Kong 24
CZ - Repubblica Ceca 23
BE - Belgio 17
EG - Egitto 17
JP - Giappone 17
TW - Taiwan 15
GR - Grecia 14
RO - Romania 14
AU - Australia 13
RU - Federazione Russa 13
PK - Pakistan 11
CH - Svizzera 9
MX - Messico 9
BR - Brasile 7
TH - Thailandia 7
ES - Italia 6
UZ - Uzbekistan 6
EU - Europa 5
SD - Sudan 5
SN - Senegal 5
TR - Turchia 5
KE - Kenya 4
ZA - Sudafrica 4
CL - Cile 3
HU - Ungheria 3
IQ - Iraq 3
IR - Iran 3
NG - Nigeria 3
NO - Norvegia 3
PS - Palestinian Territory 3
PT - Portogallo 3
BG - Bulgaria 2
CO - Colombia 2
MU - Mauritius 2
MY - Malesia 2
TG - Togo 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
CU - Cuba 1
GM - Gambi 1
HR - Croazia 1
IL - Israele 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
ME - Montenegro 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
RS - Serbia 1
UG - Uganda 1
UY - Uruguay 1
Totale 9.456
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.203
Chandler 660
Beijing 381
Dublin 370
Fairfield 260
Houston 208
Woodbridge 195
Singapore 188
Torino 178
Villeurbanne 168
Wilmington 161
Dearborn 154
Vienna 147
Nyköping 146
Ashburn 135
Medford 106
Princeton 104
Columbus 92
Cambridge 80
Fremont 80
Jacksonville 77
Seattle 73
Redwood City 72
Santa Clara 70
Guangzhou 42
Pisa 37
Milan 36
Boardman 34
Boston 31
Jakarta 27
Dong Ket 26
Toronto 24
Nanjing 22
Warsaw 22
Hefei 21
New York 20
Turin 19
Shanghai 18
Brno 17
Munich 17
Verona 16
Brussels 15
Jinan 14
Norwalk 14
Los Angeles 13
Nürnberg 13
Falls Church 12
Mountain View 12
Hong Kong 11
Taipei 11
San Diego 10
Des Moines 9
Hebei 9
Kharkiv 9
London 9
Rome 9
Cairo 8
Central District 8
Hangzhou 8
Helsinki 8
Kunming 8
Leawood 8
Hyderabad 7
Pune 7
Washington 7
Chengdu 6
Dallas 6
Pozzolo Formigaro 6
Zhengzhou 6
Edinburgh 5
Falkenstein 5
Fiano Romano 5
Nanchang 5
Phoenix 5
Silver Spring 5
Tokyo 5
Weimar 5
Zurich 5
Athens 4
Auburn Hills 4
Bari 4
Bengaluru 4
Chicago 4
Karachi 4
Nagold 4
Ottawa 4
Seoul 4
Windsor 4
Wuhan 4
Aachen 3
Bangkok 3
Bloomington 3
Bucharest 3
Buffalo 3
Chongqing 3
Cluj-napoca 3
Düsseldorf 3
Esslingen am Neckar 3
Guiyang 3
Gurgaon 3
Totale 6.122
Salva come PNG Salva come JPEG
Nome #
The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon 310
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 248
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 239
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 218
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 195
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 193
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 190
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 187
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 179
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 178
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 175
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 171
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. 170
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D 165
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 162
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 158
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 156
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 150
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 149
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 149
Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B 146
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 143
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 142
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 142
Influenza della somministrazione del metadone sulle concentrazioni plasmatiche di daclatasvir in una coorte di pazienti con epatite cronica da HCV e tossicodipendenza attiva. 138
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 138
Epidemiology, patient profile, and health care resource use for hepatitis C in Italy 131
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 129
Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. 128
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon 126
Ruolo della riduzione precoce di HBsAg per individuare i pazienti con infezione precoce da HBV, HBeAg-negativi e genotipo E ad alta probabilità di risposta sostenuta con 48 settimane di trattamento con PEG-INF ALFA-2A 123
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 119
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 111
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 110
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 108
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 105
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 101
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 100
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 99
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 98
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. 94
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy 94
Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon 92
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 92
A Case of Imported JE Acquired During Short Travel in Vietnam. Are Current Recommendations About Vaccination Broader? 91
[Primary soft tissue and tenosynovial tuberculosis after needlestick injury in a surgeon]. 90
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 88
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection 88
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 86
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 84
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 84
Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry 83
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 79
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 78
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 75
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 75
Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia 74
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage 73
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 72
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia 72
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 72
Co-infection with other respiratory pathogens in COVID-19 patients 72
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy 71
Role of intravenous immunoglobulin administration in Japanese encephalitis. 71
Combination therapy in chronic hepatitis B: what are the real benefits? 69
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 68
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients 66
Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis 64
Klebsiella pneumoniae meningitis in a 38-year-old Chinese traveller with impaired glucose tolerance: A new emerging syndrome? 61
Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis 61
Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue 61
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 60
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 59
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 59
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir. 59
UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients 59
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3 58
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 57
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study 57
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen levels in the natural history of chronic HBV infection 56
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir 56
Visceral leishmaniasis in a patient with active HBV/HDV co-infection 56
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy 55
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: A case series 53
Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all? 51
Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders 51
Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment 50
Ceftobiprole perspective: Current and potential future indications 50
Plasmatic and intracellular concentration of entecavir during treatment of a symptomatic flare in HBV-HDV decompensated cirrhosis 48
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens 44
Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG-IFN 43
EPATITE CRONICA DA HBV DI GENOTIPO E NELLA POPOLAZIONE IMMIGRATA PROVENIENTE DALL'AFRICA OCCIDENTALE 38
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 35
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing 33
Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience 32
Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B 31
The Role of IL28B Genotype in HCV-RNA Baseline Levels 30
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C 30
Flecainide plasma level modifications during the ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C 27
Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers 25
Totale 9.941
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.651
article - articoli 0
book - libri 0
conference - conferenze 5.467
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.118
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.502 0 0 0 0 181 362 148 90 89 239 181 212
2020/20211.028 159 54 41 68 91 64 51 26 69 60 132 213
2021/20221.859 141 163 140 178 120 183 165 137 107 72 258 195
2022/20231.873 156 121 54 191 177 444 116 141 248 30 125 70
2023/2024574 84 100 27 30 39 81 17 30 6 29 41 90
2024/2025553 18 93 73 164 205 0 0 0 0 0 0 0
Totale 9.969